Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q1 2025 (← Previous) (Next →)

Filing Date: May 7, 2025

Total Value ($000): $60,209 (100.0% shares, 0.0% debt)

Holdings (7)

GLUE Monte Rosa Therapeutics, Inc. 43.6%

Value ($000) $26,230 Shares 5,652,922 Est. Cost $7.50 Unrealized -18.3%

CRSP CRISPR Therapeutics AG 28.2%

Value ($000) $16,966 Shares 498,558 Est. Cost $40.26 Unrealized +5.3%

CTNM Contineum Therapeutics, Inc. 10.6%

Value ($000) $6,409 Shares 918,163 Est. Cost $16.10 Unrealized -43.5%

SKYE Skye Bioscience, Inc. 5.3%

Value ($000) $3,192 Shares 2,007,704 Est. Cost $7.75 Unrealized -64.8%

— Repare Therapeutics, Inc. 4.3%

Value ($000) $2,609 Shares 2,646,657 Est. Cost $10.58 Unrealized —

TPST Tempest Therapeutics, Inc. 4.3%

Value ($000) $2,588 Shares 3,507,055 Est. Cost $11.34 Unrealized 0.0%

— Adverum Biotechnologies, Inc. 3.7%

Value ($000) $2,215 Shares 506,821 Est. Cost $9646.10 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
GLUE	Monte Rosa Therapeutics, Inc.	5,652,922	$26,230	43.6%	$7.50	-18.3%	Common Stock	61225M102
CRSP	CRISPR Therapeutics AG	498,558	$16,966	28.2%	$40.26	+5.3%	Common Shares	H17182108
CTNM	Contineum Therapeutics, Inc.	918,163	$6,409	10.6%	$16.10	-43.5%	Common Stock	21217B100
SKYE	Skye Bioscience, Inc.	2,007,704	$3,192	5.3%	$7.75	-64.8%	Common Stock	83086J200
—	Repare Therapeutics, Inc.	2,646,657	$2,609	4.3%	$10.58	—	Common Stock	760273102
TPST	Tempest Therapeutics, Inc.	3,507,055	$2,588	4.3%	$11.34	0.0%	Common Stock	87978U207
—	Adverum Biotechnologies, Inc.	506,821	$2,215	3.7%	$9646.10	—	Common Stock	00773U108